1. Remember to follow the
clinical practice guidelines for
CML and MPD
B i o m a r k e r T e s T i n g r e c o m m e n d e d B y n c c n a n d W H o
NCCN Clinical Practice Guidelines in Oncology recommend
monitoring CML patient response to treatment with Imantinib by
periodically measuring BCR-ABL levels.
Testing for JAK2 levels is recommended in the revised 2008 WHO
guidelines diagnostic criteria for MPD.
Information provided from molecular assays for leukemias and other blood cancers can help you
and your patients make more informed decisions. Ask for JAK2 and BCR-ABL testing from your
local or reference laboratory.
For more information about the guidelines, visit http://na.ipsogen.com and select the section
for Healthcare Professionals.
IPSOGEN Inc.
700 Canal Street, Stamford, CT 06902 © 2010 IPSOGEN Inc. All rights reserved. NA_A061001JCO
203.504.8585 • www.ipsogen.com For Research Use Only. Not for use in diagnostic procedures.